We hypothesized that sequential biologic therapy with benralizumab as anti-IL-5 therapy and dupilumab, which inhibits IL-4 and IL-13 signaling, would have a significant effect in this patient based on the following reasons: (i) the inadequate response to treatment with mepolizumab and omalizumab, (ii) the effects of treatment of asthma with benralizumab, (iii) prolonged high FeNO levels, and (iv) promising data on therapeutic response to dupilumab for ECRS. Here, IL4 is linked to asthma.